What Does a Teamwork Approach to Lung Cancer Care Look Like?

Published on

Topics include: Understanding

What is multidisciplinary lung cancer care? How can patients benefit from having a radiation oncologist, medical oncologist or molecular pathologist on their healthcare team? A panel of esteemed lung cancer experts, including Dr.  Jhanelle Gray and Dr. Stephen Rosenberg, both from the Moffitt Cancer Center, describe different roles involved in a team medicine approach and how they work together to form a comprehensive treatment plan. Watch now to learn more.

This is a Patient Empowerment Network program produced by Patient Power, in partnership with Moffitt Cancer Center. We thank AbbVie, Inc., Celgene Corporation, Foundation Medicine, and Novartis for their support.

View more programs featuring , , and

Produced in association with and


Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Andrew Schorr:

We have another slide that describes the role. Really the team medicine approach, if you will. And let’s take a look at that. 

So, okay. So, Ed was referred to Moffitt. Came there for a second opinion. And so, let’s see how it goes. So, Ed was the first place you went was to an oncologist. Was that first stop for you?

Edward Cutler:            

That’s correct.

Andrew Schorr:          

Oh, okay.

Edward Cutler:            

I went to a GI oncologist.

Andrew Schorr:          

A GI oncologist? But then it was discovered that it was really coming from your chest. And there was testing done. So, Dr. Rosenberg, let’s let you lead it. So, here I see radiation oncologist, medical oncologist, way down at the bottom we have molecular pathologist, like we have Dr. Boyle. How does all this work together?

Dr. Rosenberg:            

I think you’re gonna hear this theme over and over again, but it’s really a team with all of us. Especially say we meet to go over patients in a weekly tumor board which includes both our medical oncologists, radiation oncologists, surgeons, our pathology colleagues, our radiologists. It’s really all of us together. And so, as we gather information from a new patient, we’re trying to really determine what their stage is. Usually first of all based on imaging and then trying to establish a diagnosis through the tissues that we’ve gotten. 

And once we kinda have that information we can meet as a team and kinda come up with a comprehensive treatment plan. And that includes gathering not only the tissue information, but the molecular information that Dr. Boyle really helps us put together there. And then after we have all that information gathered then we can kinda go down these different paths depending on what stage the patient has, what their molecular drivers are, and what sort of clinical trials and opportunities we have available for them that fits them in a very personalized way which really goes back to that personalized medicine that you were talking about there.

Andrew Schorr:          

Dr. Gray, any comments from you about this wheel?

Dr. Gray:                     

No, I completely agree with what Dr. Rosenberg summarized. I think we’re at—we’re a big referral center at Moffitt Cancer Center. And many times patients may come in with a biopsy. And I wanted to just touch base with what was mentioned before about getting enough tissue. When you do do biopsies to work up for the lung cancer that is very important. And I think this wheel here and this summary here helps to highlight that. That we really want to get down to the point where we’re really collaborating with the molecular pathologist looking at your biopsy within the lab. And perhaps getting that circulating tumor DNA analysis in a blood also to make this decision. 

And I fully concur that this is a team approach. We really need the pathologist to let us know what’s going on. We really need to sit down as a team and make sure that we all come up with the right decision for the patient. And that’s certainly one of the benefits of going to a place like—you mentioned Harvard and coming to the 

Moffitt Cancer Center certainly also.

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Related Programs

Lung Cancer Q&A: What Are Driver Mutations?

How do driver mutations influence lung cancer treatment decisions? Tune in to hear lung cancer experts Dr. Jhanelle Gray and Dr. Theresa Boyle explain how doctors identify unique tumor biology.


Lung Cancer Q&A: How Accurate Are Blood Biopsy Results?

How reliable are blood biopsy results when looking at genetic mutations? Lung cancer expert Dr. Theresa Ann Boyle explains the pros and cons of testing and how to help ensure the most accuracy.


Lung Cancer Q&A: When Should Patients Consider Getting a Liquid Biopsy?

Where do liquid biopsies fit in with lung cancer care? Watch to hear lung cancer expert Dr. Theresa Boyle discuss liquid biopsy purpose, value and influence of test results.


What Role Does Radiation Play in Lung Cancer Care?

Watch as lung cancer experts Dr. Jhanelle Gray and Dr. Stephen A. Rosenberg from the Moffitt Cancer Center discuss the role of radiation oncology in lung cancer care.


Ed’s Story: The Impact of Modern Medicine and Clinical Trials on My Lung Cancer

Meet Ed Cutler, a lung cancer survivor and advocate from Tampa, Fla., as he shares the ups and downs of his treatment journey; from standard care to two clinical trials, to help others understand the positive impact innovative therapies can have.


Join Our Community Register for Events Read Our Latest Blog

Page last updated on May 23, 2019